Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
77 Leser
Artikel bewerten:
(0)

Cell-based Assays Market to Reach $19.9 Billion by 2022: Analysis By Product and Service, Application, End User & Region

DUBLIN, July 19, 2017 /PRNewswire/ --

The "Cell-based Assays Market - Global Forecast to 2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The global cell-based assays market is expected to reach USD 19.92 billion by 2022, at a CAGR of 8.4% from 2017 to 2022. The major factors driving this market are the growing funding and investments in R&D, the increasing prevalence of chronic disorders, rising drug discovery activity, and the advantages of cell-based assays over alternative technologies. On the other hand, the growth of this market is hindered to some extent due to the high cost of instruments and stringent regulatory policies

The cell-based assays market is classified on the basis of products into consumables, instruments, services and software. The consumables segment is further segmented into reagents, assay kits, microplates, cell lines, probes & labels and other consumables. The consumables segment is expected to grow at the highest rate during the forecast period. This is attributed to the effective and innovative products developed and launched by various players in the market. Such products are encouraging acceptance from consumers.

The cell-based assays market is segmented by end users into pharmaceutical and biotechnology companies, academic and government institutions, contract research organizations, and other end users such as hospitals, clinical laboratories, and environmental monitoring laboratories. In 2017, pharmaceutical and biotechnology companies segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to the other segments. This positive growth can be attributed to the increasing adoption of cell-based assays for drug discovery by these end users, particularly in developed countries across North America and Europe.

Companies Mentioned

  • Aurelia Bioscience Ltd.
  • Becton, Dickinson and Company.
  • Bioagilytix Labs.
  • Biospherix, Ltd.
  • Biotek Instruments, Inc.
  • Cell Biolabs, Inc.
  • Cell Biologics Inc.
  • Cell Signaling Technology
  • Charles River Laboratories International, Inc.
  • Cisbio Bioassays
  • Danahar Corporation
  • Discoverx Corporation
  • Enzo Life Sciences, Inc.
  • Essen Bioscience
  • Ge Healthcare
  • Lonza (Switzerland)
  • Marine Biological Laboratory
  • Merck KGaA
  • Miltenyi Biotec
  • Perkinelmer Inc.
  • Promega Corporation
  • Proqinase GmbH
  • Qgel Sa
  • Selexis Sa
  • Thermo Fisher Scientific Inc.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Cell-Based Assays Market: Premium Insights

5 Market Overview

6 Cell-Based Assays Market, By Product and Service

7 Cell-Based Assays Market, By Application

8 Cell-Based Assays Market, By End User

9 Cell-Based Assays Market, By Region

10 Cell-Based Assays Market: Competitive Landscape

11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/4k6mwt/cellbased_assays

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.